

PHARMACY POLICY STATEMENT

Indiana Medicaid

DRUG NAME	Ilumya (tildrakizumab-asmn)
BILLING CODE	J3590
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Office
COVERAGE REQUIREMENTS	Prior Authorization Required (Non-Preferred Product) Alternative preferred products include Humira and Enbrel QUANTITY LIMIT— 100 mg every 12 weeks after 4 th week
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Ilumya (tildrakizumab-asmn) is a **non-preferred** product and will only be considered for coverage under the **medical** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

PLAQUE PSORIASIS (PP)

For **initial** authorization:

1. Member must be 18 years of age or older with a diagnosis of moderate-to-severe chronic plaque psoriasis (PP); AND
2. Member must have a documented negative TB test (i.e. tuberculosis skin test (PPD), an interferon-release assay (IGRA), or a chest x-ray) within 6 months prior to starting therapy; AND
3. Medication must be prescribed by a dermatologist or rheumatologist; AND
4. Member has PP for 6 months or longer; AND
5. Member is not going to receive systemic therapy or phototherapy while on Ilumya; AND
6. Member's PP involving 10% or more of the body surface area (BSA) or 5% or more of BSA if psoriasis involves sensitive areas (hands, feet, face, or genitals); AND
7. Member's Psoriasis Area and Severity Index (PASI) score ≥ 12 ; AND
8. Member's static Physician's Global Assessment (sPGA) score ≥ 3 in the overall assessment (plaque thickness/induration, erythema, and scaling); AND
9. Member has tried and failed to respond to treatment with at least one of the following:
 - a) a) At least 12 weeks of photochemotherapy (i.e. psoralen plus ultraviolet A therapy);
 - b) b) At least 12 weeks of phototherapy (i.e. UVB light therapy, Excimer laser treatments (tanning beds emit mostly UVA light and therefore would not meet this criteria));
 - c) c) At least a 4 week trial with topical antipsoriatic agents (i.e. anthralin, calcipotriene, coal tar, corticosteroids, tazarotene); AND
10. Member has tried and failed to respond to treatment of traditional oral/systemic therapies (i.e. cyclosporine, methotrexate, acitretin) for at least a 12 week trial; AND
11. Member has tried and failed to respond to treatment with **both** Enbrel and Humira.
12. **Dosage allowed:** 100 mg at Weeks 0, 4, and every twelve weeks thereafter.

If member meets all the requirements listed above, the medication will be approved for 4 months.

For **reauthorization**:

1. Member must have been retested for TB with a negative result within the past 12 months; AND
2. Member must be in compliance with all other initial criteria; AND
3. Chart notes have been provided that show the member has shown improvement of signs and symptoms of disease; AND
4. Documented member's PASI score improvement; AND
5. Documented member's sPGA score improvement.

If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.

CareSource considers Ilumya (tildrakizumab-asmn) not medically necessary for the treatment of the following disease states based on a lack of robust clinical controlled trials showing superior efficacy compared to currently available treatments:

- Active infections
- Ankylosing spondylitis
- Asthma
- Cellulitis
- Crohn's Disease
- Dissecting scalp cellulitis
- For use in combination with other TNF-inhibitors (i.e. Kineret, Enbrel, Remicade)
- Giant-cell arteritis
- Guttate psoriasis
- Infectious uveitis
- Juvenile idiopathic arthritis
- Lupus perino
- Osteoarthritis
- Psoriatic Arthritis
- Recurrent pregnancy loss
- Relapsing polychondritis
- Rheumatoid arthritis
- Sarcoidosis
- Sciatica
- Spondyloarthritis (other than ankylosing spondylitis)
- Takayasu's arteritis
- Vogt-Koyanagi

DATE	ACTION/DESCRIPTION
09/13/2018	New policy for Ilumya created.

References:

1. Ilumya [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., March, 2018.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology, Volume 65, Issue 1, 137 – 174.
3. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan;148(1):95-102.

4. ClinicalTrials.gov. Identifier NCT01225731. A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003). Available at: <https://clinicaltrials.gov/ct2/show/NCT01225731?term=tildrakizumab&rank=1>. Accessed on March 26, 2018.
5. Ed. Lebwohl MG, et al. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 5th ed. Philadelphia, PA: Saunders; 2018.
6. Bologna JL, et al. Dermatology. 4th ed. Philadelphia, PA: Saunders; 2018.
7. Feldman SR. Treatment of psoriasis. In: UpToDate. Waltham, MA: UpToDate; 2018.

Effective date: 10/01/2018

Revised date: 09/13/2018